Transient elevated serum prolactin in trans women is caused by cyproterone acetate treatment

Background

Hormonal treatment in trans women (male to female transgender persons) in Europe usually consists of the administration of estrogens combined with anti-androgens, such as cyproterone acetate (CPA). Mild elevations of serum... [ view full abstract ]

Aim(s)

To evaluate if CPA contributes in the elevation of prolactin in trans women receiving cross-sex hormones. [ view full abstract ]

Main Outcome Measures

This study is part of the endocrine part of the European Network for the Investigation of Gender Incongruence (ENIGI). Belgian data were selected for this substudy. Trans women that initiated cross-sex hormone treatment and... [ view full abstract ]

Methods

Sex steroids, gonadotropins and prolactin were measured pre and post surgery in patients receiving orchiectomy and at 6, 12 and 18 months in patients who did not undergo orchiectomy (control group). We compared pre-and... [ view full abstract ]

Results

One hundred and seven trans women participated in this analysis, with a mean age of 31.5 years. We noticed an increase in serum prolactin levels in both the intervention (23.72 µg/L) and control group (23.05 µg/L) after... [ view full abstract ]

Conclusion

CPA causes a temporary increase in serum prolactin, with prolactin levels returning to normal after orchiectomy and discontinuation of CPA. Hormone prescribing physicians and clients can be reassured that these pre-operative... [ view full abstract ]

Authors

Justine Defreyne (Ghent University Hospital, Department of Endocrinology), Nienke Nota (VUMC), Pereira Cecilia (San Juan de Dios Hospital), Thomas Schreiner (Oslo university hospital), Alessandra Fisher (university of florence), Guy T'Sjoen (Ghent University), Martin den Heijer (VUMC)

Topic Area

Oral & Poster Topics: Endocrinology

Session

OS-2C » Endocrinology II (11:00 - Friday, 7th April, Atlantic 3)

Presentation Files

EPATHDefreyneJustinePRL.pptx